Though generic drugs represent more than 90% of dispensed prescriptions, generic drug manufacturers continue to face pressure from drug distributors, pharmacy benefit managers, and competitors. But this reality doesn’t necessarily mean investors should overlook the generic drug pharmaceutical industry—in fact several leading companies are diversifying their assets for future growth.

Our latest report analyzes the US generic drug landscape, including an industry overview, historical data, deep dives into generic leaders—such as Teva, Sandoz, and Viatris—and more.

Download the report to learn how to leverage these top companies’ growth plans for your investing strategy.